UbiQ was founded in 2010 as a spin-out from the Netherlands Cancer Institute to support drug discovery in the rapidly growing ubiquitin field. 

In our laboratory at the Amsterdam Science Park, UbiQ develops, manufactures, and commercialises research tools such as ubiquitinated peptides, activity-based probes, and activity assay reagents. In addition to ubiquitin, we also offer ubiquitin-like variants (SUMO, ISG15, NEDD8, etc.) of our reagents. All these reagents are available as standard stock items in our catalogue on our website.

With our UbiQ technologies, using automated solid-phase peptide synthesis, we synthesize in a site-selective manner ubiquitinated peptides and reagents that are not readily available through biological approaches. Next to our catalogue reagents, we offer a tailored chemical approach to producing specific ubiquitinated conjugates. This custom ubiquitin synthesis approach allows researchers to design unique ubiquitinated peptides and ubiquitin reagents for drug discovery.

We sell and ship worldwide directly to our customers.
For more information, please visit www.ubiqbio.com

Next to our reagent business, we focus on developing drug discovery platforms based on ubiquitin technology.

UbiQ

Org chart

Teams

Offices